Novartis AG

Novartis AG Earnings Recaps

NVS Health Care 2 recaps
Next earnings: February 3, 2027 (estimated) · full calendar
Q3 2026 Oct 30, 2026

Novartis reported Q3 sales growth and core margin expansion, with the stock up 1.5% after earnings—within the roughly flat range. Full-year 2026 bottom-line guidance was raised, while management said meaningful acceleration in Pluvicto’s hormone-sensitive prostate cancer launch is more likely next year.

Key takeaways
  • Sales increased 4% in constant currency and core operating income rose 10%; management cited margin expansion and raised full-year 2026 bottom-line guidance.
  • Priority brands grew 29%. Kisqali sales rose 37%, Kesimpta 22%, and Leqvio 63%.
  • Pluvicto grew 20% in constant currency, but US growth was 9%. Management described the hormone-sensitive prostate cancer launch as being in its early days and expects further acceleration next year.
  • Kisqali’s early breast cancer launch was approved in 84 countries and reimbursed in 43; management reported 55% first-line new-patient share for Kisqali in US metastatic disease.
  • Leqvio’s US sales grew 60%; its share in Medicare reached 22%, according to management.
Q3 2025 Oct 28, 2025

Novartis reported robust Q3 2025 results with a 7% increase in sales and core operating income, driven by strong performance from key growth drivers and critical pipeline advancements.

Key takeaways
  • Core operating income margin held steady at 39.3%, reflecting efficient cost management amid competitive pressures.
  • Kisqali saw exceptional growth of 68%, leading in both early and metastatic breast cancer markets, with U.S. sales up 91%.
  • Kesimpta experienced 44% growth, bolstered by strong first-line patient access and significant market share in major territories.
  • Pluvicto achieved 45% growth, driven by recent approvals and increasing community adoption, supporting a path to peak sales potential.
  • Successful FDA approvals and positive Phase III data reinforce Novartis’ growth trajectory and pipeline strength.